Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | CFTR | P13569 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MMP13 | P45452 | 2/20 | 0.36 |
| ▸ | MMP1 | P03956 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.36 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL181292 | 1.00 | CYP2D6 (0.52) | CYP2D6CYP1A2CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL507364 | 1.00 | CYP2D6 (0.52) | CYP2D6CYP1A2CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL25859829 | 0.91 | CYP2D6 (0.50) | CYP2D6CYP1A2CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL21488522 | 0.91 | CYP2D6 (0.50) | CYP2D6CYP1A2CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL435571 | 0.90 | CYP2D6 (0.58) | CYP2D6CYP1A2CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL4641154 | 0.90 | CYP2D6 (0.51) | CYP2D6CYP1A2CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL25173913 | 0.90 | CYP2D6 (0.49) | CYP2D6CYP1A2CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL181141 | 0.87 | CYP2D6 (0.54) | CYP2D6CYP1A2CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL29656200 | 0.86 | CYP2D6 (0.51) | CYP2D6CYP1A2CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL21036753 | 0.84 | TSHR (0.38) | CYP2D6CYP1A2CYP3A4CYP2C19CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 306 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110683998-A | Preparation method of empagliflozin intermediate | 杭州华东医药集团浙江华义制药有限公司 | 2020-01-14 | — | — | CN | claimed |
| US-12637451-B2 | Amino quinazoline derivatives as P2X3 inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2026-05-26 | — | — | US | disclosed |
| US-12577267-B2 | Pyrimidine compounds for use as MAP4K1 inhibitors | GLENMARK SPECIALITY S.A. (CH) | 2026-03-17 | — | — | US | disclosed |
| US-20260008760-A1 | DIPEPTIDYL PEPTIDASE 1 INHIBITORS AND USES THEREOF | INSMED INCORPORATED | 2026-01-08 | — | — | US | disclosed |
| US-20250276966-A1 | Nitrogen-Linked Benzisoxazole Sulfonamide Derivatives | PFIZER (US) | 2025-09-04 | — | — | US | disclosed |
| EP-4574210-A2 | KAPPA OPIOID RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO | The Scripps Research Institute (US) | 2025-06-25 | — | — | EP | disclosed |
| EP-3853234-B1 | FUSED TRICYCLIC RING DERIVATIVES AS SRC HOMOLOGY-2 PHOSPHATASE INHIBITORS | NIKANG THERAPEUTICS INC (US) | 2025-04-23 | — | — | EP | disclosed |
| CN-119841847-A | Cyclic 2-amino-3-cyanothiophenes and derivatives thereof for the treatment of cancer | 勃林格殷格翰国际有限公司 | 2025-04-18 | — | — | CN | disclosed |
| US-20250122183-A1 | Nitrogen-Linked Benzisoxazole Sulfonamide Derivatives | PFIZER (US) | 2025-04-17 | — | — | US | disclosed |
| WO-2025074249-A1 | NITROGEN-LINKED BENZISOXAZOLE SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF CANCER | PFIZER INC. (US) | 2025-04-10 | — | — | WO | disclosed |
| WO-2006117360-A1 | CRYSTALLINE FORMS OF 1-CHLORO-4-(ß-D-GLUCOPYRANOS-1-YL)-2-[4-((R)-TETRAHYDROFURAN-3-YLOXY)-BENZYL]-BENZENE, A METHOD FOR ITS PREPARATION AND THE USE THEREOF FOR PREPARING MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-11-09 | — | — | WO | disclosed |
| EP-1638934-A1 | 3-AMINOPYRROLIDINES AS INHIBITORS OF MONOAMINE UPTAKE | ELI LILLY AND COMPANY (US) | 2006-03-29 | — | — | EP | disclosed |
| WO-2005118531-A1 | AMINOMETHYL-AZACYCLE DERIVATIVES AS INHIBITORS OF MONOAMINE UPTAKE | ELI LILLY AND COMPANY (US) | 2005-12-15 | — | — | WO | disclosed |
| EP-1594867-A2 | PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE MODULATORS | Prosidion Limited (GB) | 2005-11-16 | — | — | EP | disclosed |
| WO-2005092877-A1 | GLUCOPYRANOSYL-SUBSTITUTED BENZOL DERIVATIVES, DRUGS CONTAINING SAID COMPOUNDS, THE USE THEREOF AND METHOD FOR THE PRODUCTION THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-10-06 | — | — | WO | disclosed |
| WO-2005082859-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2005-09-09 | — | — | WO | disclosed |
| US-20050187168-A1 | Glucopyranosyloxy-substituted aromatic compounds, medicaments containing such compounds, their use and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-08-25 | — | — | US | disclosed |
| WO-2005000811-A1 | 3-AMINOPYRROLIDINES AS INHIBITORS OF MONOAMINE UPTAKE | ELI LILLY AND COMPANY (US) | 2005-01-06 | — | — | WO | disclosed |
| US-20040181067-A1 | Tri(cyclo) substituted amide compounds | OSI PHARMACEUTICALS, INC. | 2004-09-16 | — | — | US | disclosed |
| WO-2004072031-A2 | PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE MODULATORS | PROSIDION LIMITED (GB) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050187168-A1 | Glucopyranosyloxy-substituted aromatic compounds, medicaments containing such compounds, their use and process for their manufacture | SLC5A2, SLC5A1, SLC2A4 | CYP2D6 279/4885CYP1A2 388/4885CYP3A4 365/4885 |
| US-12577267-B2 | Pyrimidine compounds for use as MAP4K1 inhibitors | PTK2B, MAP3K10, MAP3K20 | CYP2D6 2556/4885CYP1A2 3111/4885CYP3A4 3045/4885 |
| US-20040181067-A1 | Tri(cyclo) substituted amide compounds | GPR119, IAPP, SLC5A1 | CYP2D6 615/4885CYP1A2 446/4885CYP3A4 422/4885 |
| US-20260008760-A1 | DIPEPTIDYL PEPTIDASE 1 INHIBITORS AND USES THEREOF | DPP9, DPP7, DPP4 | CYP2D6 79/4885CYP1A2 1328/4885CYP3A4 434/4885 |
| US-20250122183-A1 | Nitrogen-Linked Benzisoxazole Sulfonamide Derivatives | CCNI, MKI67, CCNA1 | CYP2D6 56/4885CYP1A2 723/4885CYP3A4 566/4885 |
| US-20250276966-A1 | Nitrogen-Linked Benzisoxazole Sulfonamide Derivatives | CCNI, MKI67, CCNA1 | CYP2D6 53/4885CYP1A2 732/4885CYP3A4 601/4885 |
| US-12637451-B2 | Amino quinazoline derivatives as P2X3 inhibitors | P2RX3, P2RX1, P2RX7 | CYP2D6 1148/4885CYP1A2 877/4885CYP3A4 1652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.